Lipocine announces its partner received fda approval of tlando™

Commercial launch expected in 2q 2022 salt lake city , march 29, 2022 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, announced today that antares pharma, inc. issued a press release announcing that the u.s. food and drug administration ("fda") has approved tlando™ (testosterone undecanoate), an oral treatment for testosterone replacement therapy ("trt") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. lipocine licensed the exclusive u.s. commercialization rights for tlando™ to antares pharma.
LPCN Ratings Summary
LPCN Quant Ranking